Skip to main content

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Journal articles  - Journal Article
Claiborne, JP; Tsai, H-L; Ghiaur, G; Smith, BD; Gojo, I; DeZern, AE; Ambinder, AJ; Jain, T; Prince, GT; Gondek, LP; Karantanos, T; Dalton, WB ...
Published in: Leuk Lymphoma
April 2026

Outcomes for adults with Philadelphia chromosome positive pre-B cell acute lymphoblastic leukemia (Ph + B-ALL) have improved dramatically, but questions remain regarding the optimal induction regimen and role of allogeneic hematopoietic cell transplantation (alloHCT). We analyzed 60 consecutive patients who received reduced-intensity (RII) or hyper-CVAD induction with continuous, second-generation tyrosine kinase inhibitors (TKIs). Reduced hematologic toxicity occurred after RII. Measurable residual disease (MRD) clearance by multicolor flow cytometry (MFC, 61 vs. 94%, p = 0.02) favored hyper-CVAD, but subsequent MRD-directed blinatumomab negated this difference. Four-year relapse-free survival (RFS) was 72.3% (95% confidence interval: 57.4-91.0%) and 79.8% (65.4-97.3%, p = 0.3) in RII and hyper-CVAD groups, respectively. AlloHCT, predominantly using reduced-intensity conditioning, bone marrow grafts, and post-transplant cyclophosphamide, was the only variable associated with improved overall survival on multivariate analysis. Concurrent chemotherapy and TKIs followed by blinatumomab for MRD positivity and alloHCT, all in less intensive forms, yield excellent outcomes for patients with Ph + B-ALL.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

April 2026

Volume

67

Issue

5

Start / End Page

1066 / 1079

Location

United States

Related Subject Headings

  • Young Adult
  • Tyrosine Kinase Inhibitors
  • Treatment Outcome
  • Transplantation, Homologous
  • Protein Kinase Inhibitors
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Neoplasm, Residual
  • Middle Aged
  • Male
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Claiborne, J. P., Tsai, H.-L., Ghiaur, G., Smith, B. D., Gojo, I., DeZern, A. E., … Webster, J. A. (2026). Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation. Leuk Lymphoma, 67(5), 1066–1079. https://doi.org/10.1080/10428194.2026.2628206
Claiborne, John Preston, Hua-Ling Tsai, Gabriel Ghiaur, B Douglas Smith, Ivana Gojo, Amy E. DeZern, Alex J. Ambinder, et al. “Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.” Leuk Lymphoma 67, no. 5 (April 2026): 1066–79. https://doi.org/10.1080/10428194.2026.2628206.
Claiborne, John Preston, et al. “Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.” Leuk Lymphoma, vol. 67, no. 5, Apr. 2026, pp. 1066–79. Pubmed, doi:10.1080/10428194.2026.2628206.
Claiborne JP, Tsai H-L, Ghiaur G, Smith BD, Gojo I, DeZern AE, Ambinder AJ, Jain T, Prince GT, Gondek LP, Karantanos T, Dalton WB, Levis MJ, Webster JA. Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2026 Apr;67(5):1066–1079.

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

April 2026

Volume

67

Issue

5

Start / End Page

1066 / 1079

Location

United States

Related Subject Headings

  • Young Adult
  • Tyrosine Kinase Inhibitors
  • Treatment Outcome
  • Transplantation, Homologous
  • Protein Kinase Inhibitors
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Neoplasm, Residual
  • Middle Aged
  • Male
  • Immunology